AFP and hepatocellular carcinoma: Our findings demonstrated that low AFP levels, mALBI grade 1 or 2a, and Atez/Bev-TACE sequential therapy were independent prognostic factors for patients with intermediate-stage HCC treated with Atez/Bev.